{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:59:37Z","timestamp":1777298377624,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12032-017-1021-3","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:03:45Z","timestamp":1504569825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"C.","family":"Floridi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pesapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Caspani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Barile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Del Sole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Masciocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lucignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Carrafiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"issue":"12","key":"1021_CR1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"1021_CR2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"12","key":"1021_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1440-1746.2011.06891.x","volume":"26","author":"S Schmidt","year":"2011","unstructured":"Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(12):1779\u201386.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1021_CR4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20132.","journal-title":"Hepatology"},{"issue":"15","key":"1021_CR5","doi-asserted-by":"crossref","first-page":"e3185","DOI":"10.1097\/MD.0000000000003185","volume":"95","author":"T Lan","year":"2016","unstructured":"Lan T, Chang L, Rahmathullah MN, Wu L, Yuan YF. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltim). 2016;95(15):e3185.","journal-title":"Medicine (Baltim)"},{"issue":"88","key":"1021_CR6","first-page":"20140564","volume":"2015","author":"R Duran","year":"1052","unstructured":"Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 1052;2015(88):20140564.","journal-title":"Br J Radiol"},{"issue":"2 Pt 1","key":"1021_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.RVI.0000142602.79459.90","volume":"16","author":"JE Goin","year":"2005","unstructured":"Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195\u2013203.","journal-title":"J Vasc Interv Radiol"},{"key":"1021_CR8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40336-016-0172-0","volume":"4","author":"MN Braat","year":"2016","unstructured":"Braat MN, Samim M, van den Bosch MA, Lam MG. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016;4:283\u201395.","journal-title":"Clin Transl Imaging"},{"issue":"5","key":"1021_CR9","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol"},{"key":"1021_CR10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-196209000-00013","volume":"156","author":"WG Schenk Jr","year":"1962","unstructured":"Schenk WG Jr, Mc DJ, Mc DK, Drapanas T. Direct measurement of hepatic blood flow in surgical patients: with related observations on hepatic flow dynamics in experimental animals. Ann Surg. 1962;156:463\u201371.","journal-title":"Ann Surg"},{"issue":"3","key":"1021_CR11","first-page":"517","volume":"96","author":"G Lin","year":"1984","unstructured":"Lin G, Lunderquist A, Hagerstrand I, Boijsen E. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery. 1984;96(3):517\u201326.","journal-title":"Surgery"},{"issue":"1","key":"1021_CR12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jvir.2012.09.030","volume":"24","author":"LA Donahue","year":"2013","unstructured":"Donahue LA, Kulik L, Baker T, et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2013;24(1):74\u201380.","journal-title":"J Vasc Interv Radiol"},{"key":"1021_CR13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40336-016-0195-6","volume":"4","author":"A Dieudonne","year":"2016","unstructured":"Dieudonne A, Hobbs RF, Sanchez-Garcia M, Lebtahi R. Absorbed-dose calculation for treatment of liver neoplasms with 90Y-microspheres. Clin Transl Imaging. 2016;4:273\u201382.","journal-title":"Clin Transl Imaging"},{"issue":"9","key":"1021_CR14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/01.RVI.0000235779.88652.53","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol. 2006;17(9):1425\u201339.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1021_CR15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19(6):1312\u20134.","journal-title":"Clin Cancer Res"},{"key":"1021_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.14694\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67\u201373.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"11","key":"1021_CR17","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jvir.2013.07.026","volume":"24","author":"S Tohme","year":"2013","unstructured":"Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013;24(11):1632\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1021_CR18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00270-009-9766-5","volume":"33","author":"A Riaz","year":"2010","unstructured":"Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33(6):1143\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"1021_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","volume":"61","author":"L Kulik","year":"2014","unstructured":"Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90\u00a0\u00b1\u00a0sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61(2):309\u201317.","journal-title":"J Hepatol"},{"issue":"4","key":"1021_CR20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","volume":"34","author":"B Sangro","year":"2011","unstructured":"Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34(4):422\u201331.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"1021_CR21","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology"},{"issue":"3","key":"1021_CR22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"44","key":"1021_CR23","doi-asserted-by":"crossref","first-page":"72343","DOI":"10.18632\/oncotarget.11644","volume":"7","author":"C Rognoni","year":"2016","unstructured":"Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7(44):72343\u201355.","journal-title":"Oncotarget"},{"issue":"4","key":"1021_CR24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2214\/AJR.15.14802","volume":"205","author":"N Fidelman","year":"2015","unstructured":"Fidelman N, Kerlan RK Jr. Transarterial chemoembolization and (90)Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease. AJR Am J Roentgenol. 2015;205(4):742\u201352.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1021_CR25","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826\u201337.","journal-title":"Hepatology"},{"issue":"8","key":"1021_CR26","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jvir.2010.04.012","volume":"21","author":"M Inarrairaegui","year":"2010","unstructured":"Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21(8):1205\u201312.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1021_CR27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jamcollsurg.2008.12.009","volume":"208","author":"CE Woodall","year":"2009","unstructured":"Woodall CE, Scoggins CR, Ellis SF, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg. 2009;208(3):375\u201382.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"1021_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","volume":"47","author":"LM Kulik","year":"2008","unstructured":"Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71\u201381.","journal-title":"Hepatology"},{"issue":"2","key":"1021_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3892\/mco.2015.705","volume":"4","author":"P Huang","year":"2016","unstructured":"Huang P, Liu C, Li B, et al. Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma. Mol Clin Oncol. 2016;4(2):229\u201336.","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"1021_CR30","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214\u201321.","journal-title":"Cancer"},{"issue":"8","key":"1021_CR31","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mds112","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23(8):1954\u201362.","journal-title":"Ann Oncol"},{"issue":"4","key":"1021_CR32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0925-5710(96)00558-0","volume":"65","author":"T Intragumtornchai","year":"1997","unstructured":"Intragumtornchai T, Rojnukkarin P, Swasdikul D, Vajanamarhutue C, Israsena S. Anemias in Thai patients with cirrhosis. Int J Hematol. 1997;65(4):365\u201373.","journal-title":"Int J Hematol"},{"issue":"9","key":"1021_CR33","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","volume":"9","author":"KS Albain","year":"1991","unstructured":"Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618\u201326.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1021_CR34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(01)01488-2","volume":"50","author":"CM Glaser","year":"2001","unstructured":"Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50(3):705\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1021_CR35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/oxfordjournals.annonc.a058423","volume":"4","author":"H Ludwig","year":"1993","unstructured":"Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1993;4(2):161\u20137.","journal-title":"Ann Oncol"},{"issue":"4 Suppl 6","key":"1021_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(00)90062-3","volume":"37","author":"S Soignet","year":"2000","unstructured":"Soignet S. Management of cancer-related anemia: epoetin alfa and quality of life. Semin Hematol. 2000;37(4 Suppl 6):9\u201313.","journal-title":"Semin Hematol"},{"issue":"3","key":"1021_CR37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","volume":"15","author":"J Glaspy","year":"1997","unstructured":"Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997;15(3):1218\u201334.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1021_CR38","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","volume":"16","author":"GD Demetri","year":"1998","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998;16(10):3412\u201325.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1021_CR39","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19(11):2875\u201382.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1021_CR40","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865\u201374.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1021_CR41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","volume":"95","author":"J Crawford","year":"2002","unstructured":"Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95(4):888\u201395.","journal-title":"Cancer"},{"issue":"11","key":"1021_CR42","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jvir.2013.07.011","volume":"24","author":"N Hamoui","year":"2013","unstructured":"Hamoui N, Minocha J, Memon K, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol. 2013;24(11):1743\u20135.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1021_CR43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00270-013-0600-8","volume":"36","author":"AH Mahnken","year":"2013","unstructured":"Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol. 2013;36(3):613\u201322.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1021_CR44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00270-008-9498-y","volume":"32","author":"M Pech","year":"2009","unstructured":"Pech M, Kraetsch A, Wieners G, et al. Embolization of the gastroduodenal artery before selective internal radiotherapy: a prospectively randomized trial comparing platinum-fibered microcoils with the Amplatzer Vascular Plug II. Cardiovasc Interv Radiol. 2009;32(3):455\u201361.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"5","key":"1021_CR45","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00270-016-1310-9","volume":"39","author":"AS Borggreve","year":"2016","unstructured":"Borggreve AS, Landman AJ, Vissers CM, et al. Radioembolization: is prophylactic embolization of hepaticoenteric arteries necessary? A systematic review. Cardiovasc Interv Radiol. 2016;39(5):696\u2013704.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"12","key":"1021_CR46","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00330-013-2951-6","volume":"23","author":"R Faletti","year":"2013","unstructured":"Faletti R, Cassinis MC, Fonio P, et al. Diffusion-weighted imaging and apparent diffusion coefficient values versus contrast-enhanced MR imaging in the identification and characterisation of acute pyelonephritis. Eur Radiol. 2013;23(12):3501\u20138.","journal-title":"Eur Radiol"},{"issue":"6","key":"1021_CR47","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","volume":"57","author":"W Sieghart","year":"2013","unstructured":"Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2261\u201373.","journal-title":"Hepatology"},{"issue":"6","key":"1021_CR48","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1148\/rg.336135511","volume":"33","author":"FD Gonzalez-Guindalini","year":"2013","unstructured":"Gonzalez-Guindalini FD, Botelho MP, Harmath CB, et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics. 2013;33(6):1781\u2013800.","journal-title":"Radiographics"},{"issue":"3","key":"1021_CR49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1021_CR50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1021_CR51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.24050","volume":"115","author":"A Forner","year":"2009","unstructured":"Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616\u201323.","journal-title":"Cancer"},{"issue":"2","key":"1021_CR52","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2011.04.028","volume":"56","author":"JH Shim","year":"2012","unstructured":"Shim JH, Lee HC, Won HJ, et al. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol. 2012;56(2):406\u201311.","journal-title":"J Hepatol"},{"issue":"6","key":"1021_CR53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","volume":"55","author":"R Gillmore","year":"2011","unstructured":"Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309\u201316.","journal-title":"J Hepatol"},{"issue":"2","key":"1021_CR54","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.2252011604","volume":"225","author":"SR Prasad","year":"2002","unstructured":"Prasad SR, Jhaveri KS, Saini S, et al. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology. 2002;225(2):416\u20139.","journal-title":"Radiology"},{"issue":"4","key":"1021_CR55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/02841861003705794","volume":"49","author":"C Suzuki","year":"2010","unstructured":"Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol. 2010;49(4):509\u201314.","journal-title":"Acta Oncol"},{"issue":"6","key":"1021_CR56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ejrad.2013.02.018","volume":"82","author":"B Zhao","year":"2013","unstructured":"Zhao B, Tan Y, Bell DJ, et al. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol. 2013;82(6):959\u201368.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1021_CR57","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1148\/radiol.11102330","volume":"260","author":"S Bonekamp","year":"2011","unstructured":"Bonekamp S, Jolepalem P, Lazo M, et al. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011;260(3):752\u201361.","journal-title":"Radiology"},{"issue":"7","key":"1021_CR58","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00330-009-1327-4","volume":"19","author":"M Mantatzis","year":"2009","unstructured":"Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P. Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol. 2009;19(7):1809\u201316.","journal-title":"Eur Radiol"},{"issue":"875","key":"1021_CR59","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1259\/bjr.73.875.11144795","volume":"73","author":"SA Sohaib","year":"2000","unstructured":"Sohaib SA, Turner B, Hanson JA, et al. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol. 2000;73(875):1178\u201384.","journal-title":"Br J Radiol"},{"issue":"2","key":"1021_CR60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497\u2013507 e92.","journal-title":"Gastroenterology"},{"key":"1021_CR61","first-page":"3457","volume":"8","author":"VH Lee","year":"2015","unstructured":"Lee VH, Leung DK, Luk MY, et al. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther. 2015;8:3457\u201364.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"1021_CR62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A Fouly El","year":"2015","unstructured":"El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627\u201335.","journal-title":"Liver Int"},{"issue":"3","key":"1021_CR63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1091-255X(01)80051-2","volume":"5","author":"RS Stubbs","year":"2001","unstructured":"Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294\u2013302.","journal-title":"J Gastrointest Surg."},{"key":"1021_CR64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2407-5-132","volume":"5","author":"L Lim","year":"2005","unstructured":"Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.","journal-title":"BMC Cancer"},{"issue":"7","key":"1021_CR65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/01.RVI.0000161142.12822.66","volume":"16","author":"R Murthy","year":"2005","unstructured":"Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16(7):937\u201345.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1021_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1\u201315.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"1021_CR67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jvir.2012.01.059","volume":"23","author":"CL Wright","year":"2012","unstructured":"Wright CL, Werner JD, Tran JM, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol. 2012;23(5):669\u201374.","journal-title":"J Vasc Interv Radiol"},{"key":"1021_CR68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40336-016-0188-5","volume":"4","author":"M Maccauro","year":"2016","unstructured":"Maccauro M, Salem R. The impact of clinical factor on dosimetry in radioembolisation. Clin Transl Imaging. 2016;4:225\u20137.","journal-title":"Clin Transl Imaging"},{"issue":"3","key":"1021_CR69","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00270-015-1088-1","volume":"38","author":"M Powerski","year":"2015","unstructured":"Powerski M, Busse A, Seidensticker M, et al. Prophylactic embolization of the cystic artery prior to radioembolization of liver malignancies\u2014an evaluation of necessity. Cardiovasc Interv Radiol. 2015;38(3):678\u201384.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"5","key":"1021_CR70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jvir.2008.01.003","volume":"19","author":"B Atassi","year":"2008","unstructured":"Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19(5):691\u20137.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"1021_CR71","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jvir.2016.09.002","volume":"28","author":"TJ Ward","year":"2017","unstructured":"Ward TJ, Louie JD, Sze DY. Yttrium-90 radioembolization with resin microspheres without routine embolization of the gastroduodenal artery. J Vasc Interv Radiol. 2017;28(2):246\u201353.","journal-title":"J Vasc Interv Radiol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1021-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:04:28Z","timestamp":1570061068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1021-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1021-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"article-number":"174"}}